Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Arthritis, Rheumatoid: full-pipeline trial registry
5 of 29 indexed Arthritis, Rheumatoid trials are currently recruiting.
Corpus placement: #552 of 28,707 conditions by registered trial count.
29 US clinical trials · 5 currently recruiting · #552 of 28,707 conditions by registered trial count
Arthritis, Rheumatoid: 29 US clinical trials tracked, 5 recruiting.
Arthritis, Rheumatoid is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 7 of these trials.
Enrollment posture brief
Registry condition arthritis-rheumatoid
OPEN 5 | RECR 17% | LATE 9 | EARLY 9 | RANK #552 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Influenza (17% recruiting · 157 trials)
Arthritis, Rheumatoid lists 5 open slots (17% of 29 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Arthritis, Rheumatoid on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Arthritis, Rheumatoid is recruiting below its size-band peers.
5 of 29 indexed trials (17.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Arthritis, Rheumatoid research.
Pfizer accounts for 7 of 29 trials (24.1%). 20 distinct sponsors appear on at least one study for this condition label.
-
Typical Arthritis, Rheumatoid enrolment sits around 298 participants.
Median target enrolment is 298 among the 28 trials that report a genuine target (sentinel values excluded). 6 of those (21.4%) plan for fewer than 100 participants.
-
Arthritis, Rheumatoid splits between interventional and observational designs.
20 interventional and 9 observational studies make up this index (69% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
29 total, page 1 of 1
IMPACT - AndHealth Autoimmune Research Registry
AndHealth
NCT05883371
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Merck Sharp & Dohme
NCT07176390
Chronic Pain in Rheumatoid Arthritis
Northwestern University
NCT05038553
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
University of Michigan
NCT00748254
R-2487 in Patients With Rheumatoid Arthritis
Rise Therapeutics
NCT05961592
INFINITY™ With ADAPTIS™ Technology Study
Stryker Trauma and Extremities
NCT04594993
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Pfizer
NCT02092467
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
GlaxoSmithKline
NCT00113308
A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
Boehringer Ingelheim
NCT00042068
Gamma Vacuum Foil (GVF) Versus Cross-linked Polyethylene in Total Knee Arthroplasty Study
DePuy Orthopaedics
NCT00289133
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
Pfizer
NCT00856544
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Boehringer Ingelheim
NCT02137226
A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis
Pfizer
NCT00814307
Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis
Pfizer
NCT00413660
The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT00001375
Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
Amgen
NCT02114931
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
Janssen Biotech
NCT01004432
Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis
Boehringer Ingelheim
NCT02640612
A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day
Pfizer
NCT04267380
Prognostic Indicators and Determinants of the 2-5 Year Outcome in a Cohort of Early Synovitis Patients
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT00001679
Real-world Clinical Efficacy of Abatacept in the T3 Data Registry
Arthritis Northwest P
NCT01555879
Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550
Pfizer
NCT00414661
A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis
Eli Lilly and Company
NCT00380744
Stepping Up For Inflammatory Arthritis
University of Pennsylvania
NCT02912221
Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA
Navidea Biopharmaceuticals
NCT02865434
Low Dose Naltrexone for Chronic Pain From Arthritis
VA Office of Research and Development
NCT03008590
A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate
Pfizer
NCT00620685
6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection
Protalex
NCT02330445
Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00440492
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 4 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Arthritis, Rheumatoid records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Arthritis, Rheumatoid trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Arthritis, Rheumatoid page
29 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Arthritis, Rheumatoid trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Arthritis, Rheumatoid trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Arthritis, Rheumatoid condition card totals 29 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.